Neurocrine Biosciences Aktie
WKN: 900964 / ISIN: US64125C1099
17.03.2025 14:54:51
|
Neurocrine Biosciences Presents New Data From KINECT-HD Study Of Ingrezza
(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) Monday said it presented positive data from Phase 3 KINECT-HD study evaluating Ingrezza capsule in adults with Huntington's disease at the Neuroscience Advanced Practice Provider Symposium hosted by the American Association of Neuroscience Nurses in New Orleans.
Data from the study showed that treatment with Ingrezza demonstrated a significant reduction in chorea severity in patients with Huntington's disease, a genetic neurodegenerative disease. This post-hoc analysis was conducted to assess the effect of Ingrezza on chorea by individual body region.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Neurocrine Biosciences Inc.mehr Nachrichten
Analysen zu Neurocrine Biosciences Inc.mehr Analysen
Aktien in diesem Artikel
Neurocrine Biosciences Inc. | 116,65 | 1,74% |
|